Pulmonary arterial hypertension and nifedipine : (Record no. 92221)

MARC details
000 -LEADER
fixed length control field 04943cam a2200601 i 4500
001 - CONTROL NUMBER
control field ocn912875317
003 - CONTROL NUMBER IDENTIFIER
control field OCoLC
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20221128212922.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS--GENERAL INFORMATION
fixed length control field m d
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr |||||||||||
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 150323s2015 nyua ob 001 0 eng
010 ## - LIBRARY OF CONGRESS CONTROL NUMBER
LC control number 2020679081
040 ## - CATALOGING SOURCE
Original cataloging agency DLC
019 ## -
-- 918623642
-- 957737140
-- 958083084
-- 963734581
-- 967769860
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
ISBN 9781634826358
Qualifying information ebook
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
ISBN 1634826353
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Cancelled/invalid ISBN 1634825942
Qualifying information hardback
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Cancelled/invalid ISBN 9781634825948
Qualifying information hardback
035 ## - SYSTEM CONTROL NUMBER
System control number 1020628
-- (N$T)
035 ## - SYSTEM CONTROL NUMBER
System control number (OCoLC)912875317
Canceled/invalid control number (OCoLC)918623642
-- (OCoLC)957737140
-- (OCoLC)958083084
-- (OCoLC)963734581
-- (OCoLC)967769860
072 #7 - SUBJECT CATEGORY CODE
Subject category code HEA
Subject category code subdivision 039000
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED
Subject category code subdivision 014000
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED
Subject category code subdivision 022000
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED
Subject category code subdivision 112000
Source bisacsh
072 #7 - SUBJECT CATEGORY CODE
Subject category code MED
Subject category code subdivision 045000
Source bisacsh
049 ## - LOCAL HOLDINGS (OCLC)
Holding library MAIN
245 00 - TITLE STATEMENT
Title Pulmonary arterial hypertension and nifedipine :
Subtitle pathogenesis and management
Statement of responsibility, etc
Medium [E-Book]
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture New York :
Name of producer, publisher, distributor, manufacturer Nova Biomedical,
Date of production, publication, distribution, manufacture, or copyright notice [2015]
300 ## - PHYSICAL DESCRIPTION
Physical description 1 online resource.
336 ## - CONTENT TYPE
Content type term text
Content type code txt
Source rdacontent
337 ## - MEDIA TYPE
Media type term computer
Media type code c
Source rdamedia
338 ## - CARRIER TYPE
Carrier type term online resource
Carrier type code cr
Source rdacarrier
490 1# - SERIES TITLE
Series statement New developments in medical research
504 ## - BIBLIOGRAPHY, ETC. NOTE
Bibliography, etc Includes bibliographical references and index.
505 0# - CONTENTS
Contents Chapter I: Mechanisms of Vascular Remodeling in Pulmonary Arterial Hypertension; Abstract; Introduction; Classification; Symptoms and Diagnosis; Biomarkers; Pathogenesis of PAH; i) Role of Endothelial Cells and Their Cross Talk with Different Cell Types in Vasculature; Endothelial Response to Injury; Endothelial Dysfunction and Vasoconstriction/Vasodilatation.
505 8# - CONTENTS
Contents Endothelial Dysfunction and Impaired AngiogenesisEndothelial Dysfunction and Plexiform Lesions; ii) Role of Inflammation and Autoimmunity; Inflammatory Cells; Cytokines and Chemokines; Molecular Mechanisms Contributing to PAH-PASMC and PAEC Proliferation and Resistance to Apoptosis; The Src/STAT3 Integrative Hub; Metabolic Switch: The Warburg Effect; Epigenetic Mechanisms of PH; Role for miRNAs; DNA Methylation; Modification of Histone Proteins; Potential Implication of Long Noncoding RNA; Vascular Stiffening in PAH: A Cause; or Consequence?; Treatment.
505 8# - CONTENTS
Contents Basic Measures and Conventional TherapiesApproved PAH Therapies; 1) Prostacyclin Pathway; 2) Endothelin Pathway; 3) Nitric Oxide-cGMP Pathway; New Drugs in Early Phase of Development; i) Newer Agents Targeting Established Vasodilatory Pathways; ii) Tyrosine Kinase Inhibition; iii) Serotonin System; iv) Vasoactive Intestinal Peptide; v) RhoA/Rho-Kinase Signaling Pathway; vi) Statins; vii) Apelin; viii) Anti-inflammatory therapies; ix) Restoration of BMPR-II Signaling Axis; Procedures/Nonmedical Therapies; Expected Novel Drugs in Future/ Therapies under Investigation; Gap in Knowledge.
505 8# - CONTENTS
Contents Iv) Neprilysin Knockout ModelOverexpression Models; i) Interleukin-6 Overexpression Model; ii) S100A4/Mts-1 Overexpression Model; Methods to Study PAH; In-vitro Methods; I. Isolation and Culture of Primary Cells; i) Human pulmonary artery endothelial cells from transplant donors; ii) Isolation of pulmonary artery smooth muscle cells; Method; Histological and Morphological Analysis; 1. Hematoxylin and Eosin (H & E) Staining; H & E Staining of Frozen Sections of Pulmonary Artery; Method; H & E Staining for Parrafin Sections of Pulmonary Artery; Method; 2. Masson's Trichrome Staining; Procedure.
520 ## - ABSTRACT
Abstract Pulmonary arterial hypertension (PAH) is a progressive, fatal syndrome characterized by increased vascular resistance that leads to right-ventricular hypertrophy and heart failure, eventually leading to death. The chapters of this book describe the molecular mechanisms and cellular events regulating vascular remodeling in PAH; the various animal models and drugs currently being used in various laboratories to study mechanisms leading to pulmonary arterial hypertension; and nifedipine, its pharmacology and it's role in the management of pulmonary hypertension and some of the drawbacks concernin.
590 ## - LOCAL NOTE (RLIN)
Local note Master record variable field(s) change: 050, 082
650 #0 - SUBJECT HEADINGS
Subject term Pulmonary hypertension.
650 #0 - SUBJECT HEADINGS
Subject term Pulmonary hypertension
General subdivision Chemotherapy.
650 #0 - SUBJECT HEADINGS
Subject term Nifedipine
General subdivision Therapeutic use.
700 1# - ADDED PERSONAL NAME
Added personal author Estrada, Victoria
Titles and other words associated with a name (Editor),
Relator term editor.
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title New developments in medical research.
856 40 - ONLINE RESOURCE
Uniform Resource Identifier <a href="https://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=1020628">https://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=1020628</a>
Link text Kingston Hospital NHS Foundation Trust OpenAthens account holders click here for access
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Suppress in OPAC Do not Suppress in OPAC
588 ## - SOURCE OF DESCRIPTION NOTE
Source of description note Description based on print version record.
938 ## -
-- YBP Library Services
-- YANK
-- 12512606
938 ## -
-- EBSCOhost
-- EBSC
-- 1020628
938 ## -
-- ProQuest Ebook Central
-- EBLB
-- EBL2130687
994 ## -
-- 92
-- N$T
Holdings
Withdrawn status Lost status Damaged status Not for loan Home library Current library Shelving location Date acquired Source of acquisition Total Checkouts Date last seen Uniform Resource Identifier Price effective from Koha item type
        Stenhouse Library Stenhouse Library   28/11/2022 eBook EBSCO clinical collection   28/11/2022 https://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=1020628 28/11/2022 Electronic book
London Health Libraries Koha Consortium privacy notice